Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-02
2011-08-02
Boesen, Agnieszka (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C424S218100, C435S005000
Reexamination Certificate
active
07989425
ABSTRACT:
The present invention relates to a vaccine enhancing the protective immunity to Hepatitis C virus using plasmid DNA and recombinant adenovirus, more particularly to a vaccine consisting of Δ core-E1-E2 expressing DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA vaccine, nonstructural protein NS5 expressing DNA vaccine and recombinant adenovirus vaccine, and method for administration of the vaccine by priming with the DNA vaccines described above and boosting with the recombinant adenovirus vaccine thereby enhancing the protective immunity to Hepatitis C virus.
REFERENCES:
patent: 5731172 (1998-03-01), Saito et al.
Pancholi et al. Jan. 2003, J. Virology, vol. 77, p. 382-390.
Tang et al. May 2002, Hep. Pancreatic Disease, vol. 1, p. 228-231.
Lechmann et al. 2000, Semin. Liver. Diseses, vol. 20, p. 211-226.
Mikkelsen et al. 2007, Current Infect. Disese Reports, vol. 9, p. 94-101.
Lee et al. Virology, 2001, vol. 279, p. 271-279.
Encke (Journal of Immunology 1998, vol. 161, p. 4917-4923).
Choo (PNAS, 1994, vol. 91, p. 1294-1298).
Large (Journal of Immunology, 1999, vol. 162, p. 931-938).
Xavier Forns, et al., Vaccination of Chimpanzees With Plasmid DNA Encoding the Hepatitis C Virus (HCV) Envelope E2 Protein Modified . . . Hepathology Vo. 32, No. 3, 2000.
Christine B. Bruce, et al. Replication-Deficient Recombinant Adenoviruses Expressing the Human Immunodeficiency Virus Env Antigen . . . Journal of General Virology (1999), 80, 2621-2628, Printed in Great Britain.
Nourredine Himoudi et al., Cornparative Vaccine Studies in HLA-A2.1-Transgenic Mice Reveal a Clustered Organization of Eptiopes . . . Journal of Virology, Dec. 2002, pp. 12735-12746; vol. 76, No. 24.
John W. Shiver, et al., Replication-Incompetent Adenoviral Vaccine Vector Elicits Effective Anti-Immunodeficiency-Virus Immunity, Nature, vol. 415, Jan. 17, 2002.
Rama Rao Amara, et al., Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine, Science vol. 292, Apr. 6, 2001.
Young Rim Seong, et al., Immunogenicity of the E1E2 Proteins of Hepatitis C Virus Expressed by Recombinant Adenoviruses, Vaccine 19, (2001) 2955-2964.
A: Farci, et al., 1992 “Lack of Protective Immunity Against Reinfection with Hepatitis C”Virus Science258;135-140.
Lechmann, et al., 2000 “Vaccine Development for Hepatitis C”Seminars in Liver Disease20(2):211-226.
Lechner et al., 2000J. Exp. Med. 191(9): 1499-1512.
Et al., 2002, “New Therapeutic Strategies for Hepatitis C,”Hepatology. 35(1):224-231.
Houghton et al., 2005 “Prospects for a vaccine against the hepatitis C virus”Nature Insights, 436:961-936.
Lee Chang Geun
Park Su-Hyung
Sung Young Chul
Yang Se-Hwan
Youn Jin-Won
Boesen Agnieszka
Daewood Co., Ltd.
Dong-A Pharm. Co., Ltd.
Genexine Inc.
Lucas & Mercanti
LandOfFree
Vaccine enhancing the protective immunity to hepatitis c... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine enhancing the protective immunity to hepatitis c..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine enhancing the protective immunity to hepatitis c... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729875